ES2542227T3 - Tratamiento de complicaciones vasculares de diabetes - Google Patents
Tratamiento de complicaciones vasculares de diabetes Download PDFInfo
- Publication number
- ES2542227T3 ES2542227T3 ES10166637.8T ES10166637T ES2542227T3 ES 2542227 T3 ES2542227 T3 ES 2542227T3 ES 10166637 T ES10166637 T ES 10166637T ES 2542227 T3 ES2542227 T3 ES 2542227T3
- Authority
- ES
- Spain
- Prior art keywords
- diabetes
- treatment
- vascular complications
- natural
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 230000002792 vascular Effects 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Péptido que consiste en 7-17 aminoácidos e incluye el hexámero TX1EX2X3E, en la que X1, X2 y X3 pueden ser cualquier aminoácido natural o no natural, en el que el péptido no muestra actividad de unión al receptor de TNF y es cíclico, para su uso en el tratamiento o la prevención de complicaciones vasculares en pacientes con diabetes.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20100166637 EP2397151B1 (en) | 2010-06-21 | 2010-06-21 | Treatment of vascular complications of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2542227T3 true ES2542227T3 (es) | 2015-08-03 |
Family
ID=42562567
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10166637.8T Active ES2542227T3 (es) | 2010-06-21 | 2010-06-21 | Tratamiento de complicaciones vasculares de diabetes |
| ES10771018T Active ES2933405T3 (es) | 2010-06-21 | 2010-10-20 | Tratamiento de complicaciones vasculares de diabetes |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10771018T Active ES2933405T3 (es) | 2010-06-21 | 2010-10-20 | Tratamiento de complicaciones vasculares de diabetes |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9359419B2 (es) |
| EP (2) | EP2397151B1 (es) |
| JP (1) | JP5878922B2 (es) |
| KR (1) | KR101752260B1 (es) |
| CN (1) | CN102946897B (es) |
| AU (1) | AU2010355825B9 (es) |
| BR (1) | BR112012033045A2 (es) |
| CA (1) | CA2800261C (es) |
| DK (1) | DK2397151T3 (es) |
| ES (2) | ES2542227T3 (es) |
| MX (1) | MX2012014195A (es) |
| PL (1) | PL2397151T3 (es) |
| RU (1) | RU2545718C2 (es) |
| WO (1) | WO2011160664A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT509267A1 (de) * | 2010-01-14 | 2011-07-15 | Apeptico Forschung & Entwicklung Gmbh | Organische verbindungen zur regulierung von vektoriellen ionenkanälen |
| DK2988768T3 (da) * | 2013-04-23 | 2021-06-21 | Apeptico Forschung & Entwicklung Gmbh | Lyofilisat indeholdende et cyklisk peptid med Formel X1-GQRETPEGAEAKPWY-X2 til behandling af pulmonære ødemer |
| ES2791225T3 (es) * | 2014-03-04 | 2020-11-03 | Apeptico Forschung & Entwicklung Gmbh | Atenuación de la inflamación intrapulmonar |
| KR102316762B1 (ko) * | 2014-03-18 | 2021-10-26 | 아펩티코 포어슝 운트 엔트빅크룽 게엠베하 | 건조 분말 펩티드 약제 |
| KR20230008844A (ko) | 2020-05-08 | 2023-01-16 | 아펩티코 포어슝 운트 엔트빅크룽 게엠베하 | Covid-19의 예방 또는 치료를 위한 펩티드 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1181886C (zh) * | 1998-08-14 | 2004-12-29 | 基因创新有限公司 | Tnf来源的肽在治疗水肿中的应用 |
| ATE457736T1 (de) * | 2004-08-06 | 2010-03-15 | Nycomed Gmbh | Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid |
| EP2009023A1 (en) * | 2007-06-04 | 2008-12-31 | Rentschler Beteiligungs GmbH | Novel peptides and their use for the treatment of edema |
| AT507953B1 (de) | 2009-03-05 | 2011-02-15 | Apeptico Forschung & Entwicklung Gmbh | Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität |
-
2010
- 2010-06-21 DK DK10166637.8T patent/DK2397151T3/en active
- 2010-06-21 ES ES10166637.8T patent/ES2542227T3/es active Active
- 2010-06-21 EP EP20100166637 patent/EP2397151B1/en active Active
- 2010-06-21 PL PL10166637T patent/PL2397151T3/pl unknown
- 2010-10-20 BR BR112012033045A patent/BR112012033045A2/pt not_active IP Right Cessation
- 2010-10-20 JP JP2013515709A patent/JP5878922B2/ja active Active
- 2010-10-20 KR KR1020127031163A patent/KR101752260B1/ko not_active Expired - Fee Related
- 2010-10-20 WO PCT/EP2010/006408 patent/WO2011160664A1/en not_active Ceased
- 2010-10-20 US US13/805,839 patent/US9359419B2/en active Active
- 2010-10-20 CN CN201080067594.8A patent/CN102946897B/zh active Active
- 2010-10-20 CA CA2800261A patent/CA2800261C/en not_active Expired - Fee Related
- 2010-10-20 MX MX2012014195A patent/MX2012014195A/es not_active Application Discontinuation
- 2010-10-20 RU RU2013102344/10A patent/RU2545718C2/ru active
- 2010-10-20 ES ES10771018T patent/ES2933405T3/es active Active
- 2010-10-20 EP EP10771018.8A patent/EP2582385B1/en active Active
- 2010-10-20 AU AU2010355825A patent/AU2010355825B9/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| PL2397151T3 (pl) | 2015-10-30 |
| DK2397151T3 (en) | 2015-05-18 |
| US20130116200A1 (en) | 2013-05-09 |
| AU2010355825A1 (en) | 2013-01-31 |
| AU2010355825B2 (en) | 2014-10-16 |
| RU2545718C2 (ru) | 2015-04-10 |
| CN102946897B (zh) | 2017-12-12 |
| JP2013530970A (ja) | 2013-08-01 |
| EP2397151A1 (en) | 2011-12-21 |
| EP2582385B1 (en) | 2022-11-16 |
| JP5878922B2 (ja) | 2016-03-08 |
| CA2800261C (en) | 2018-01-02 |
| CA2800261A1 (en) | 2011-12-29 |
| BR112012033045A2 (pt) | 2017-06-20 |
| ES2933405T3 (es) | 2023-02-08 |
| RU2013102344A (ru) | 2014-07-27 |
| KR101752260B1 (ko) | 2017-06-29 |
| WO2011160664A1 (en) | 2011-12-29 |
| KR20130127359A (ko) | 2013-11-22 |
| US9359419B2 (en) | 2016-06-07 |
| EP2397151B1 (en) | 2015-04-22 |
| EP2582385A1 (en) | 2013-04-24 |
| MX2012014195A (es) | 2013-02-07 |
| AU2010355825B9 (en) | 2015-02-05 |
| CN102946897A (zh) | 2013-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2512141T3 (es) | Análogo peptídico de oxintomodulina | |
| ES2486675T3 (es) | Análogo de péptido de oxintomodulina | |
| ES2540858T3 (es) | Composición farmacéutica para el tratamiento y/o la prevención de cáncer | |
| CO2020009625A2 (es) | Inhibidor de fap | |
| ES2494316T3 (es) | Ingrediente activo novedoso en cicatrización y uso del mismo | |
| ES2542227T3 (es) | Tratamiento de complicaciones vasculares de diabetes | |
| CL2012003026A1 (es) | Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad. | |
| ES2616658T3 (es) | Péptidos que mimetizan el factor de crecimiento y sus usos | |
| ES2525758T3 (es) | Composición que comprende un péptido y un inhibidor de la neuraminidasa vírica | |
| ES2650463T3 (es) | Tratamiento de enfermedades inflamatorias con ACE2 | |
| ES2513392T3 (es) | Materiales biológicos y usos de los mismos | |
| ES2666720T3 (es) | Composición para prevenir o tratar el cáncer de cuello uterino con un potenciador de la inmunidad contra el virus de papiloma humano | |
| CY1121042T1 (el) | Φαρμακοτεχνικες μορφες ινσουλινων μακρας-δρασεως | |
| RU2015149010A (ru) | Биологические маркеры, которые могут быть использованы в иммунотерапии рака | |
| CL2012002031A1 (es) | Composición farmacéutica que contiene al menos un compuesto fgf-21 (factor de crecimiento de fibroblastos 21) y al menos un agonista del glp-1r (receptor del péptido 1 similar al glucagón); y su uso para preparara un medicamento para el tratamiento de al menos un síndrome metabólico y/o aterosclerosis en un paciente. | |
| BRPI0917315B8 (pt) | anticorpo monoclonal, seu uso e composição farmacêutica o compreendendo | |
| BRPI0814097A8 (pt) | Derivado do peptídeo insulinotrópico cm seu aminoácido n-terminal modificado | |
| PE20140617A1 (es) | Alfa glucosidasa acida modificada con procesamiento acelerado | |
| BR112015009037A2 (pt) | composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1 | |
| BR112013032088A2 (pt) | "polipeptídeo, composição farmacêutica e seu uso" | |
| EA201500061A1 (ru) | Фармацевтическая композиция для терапии легочной формы высотной болезни, вызванной кислородным голоданием и пониженным атмосферным давлением | |
| BR112013019513A2 (pt) | métodos para o tratamento de úlceras diabéticas do pé | |
| ES2482168T3 (es) | Uso de opioides del grupo de la metadona para el tratamiento de pacientes con cáncer resistente | |
| BRPI0720230A2 (pt) | Uso de uma formulação nutricional oralmente administrável, formulação nutricional, método para tratar um distúrbio desenvolvimental penetrante, e, composição | |
| CU23701A1 (es) | Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i |